- Home
- TLSA vs CGTX Comparison
TLSA vs CGTX Comparison
Compare TLSA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CGTX
- Stock Information
- Founded
- TLSA 2013
- CGTX 2007
- Country
- TLSA United Kingdom
- CGTX United States
- Employees
- TLSA N/A
- CGTX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- CGTX Health Care
- Exchange
- TLSA Nasdaq
- CGTX Nasdaq
- Market Cap
- TLSA 87.8M
- CGTX 79.3M
- IPO Year
- TLSA 2000
- CGTX 2021
- Fundamental
- Price
- TLSA $1.20
- CGTX $0.54
- Analyst Decision
- TLSA
- CGTX Buy
- Analyst Count
- TLSA 0
- CGTX 6
- Target Price
- TLSA N/A
- CGTX $8.00
- AVG Volume (30 Days)
- TLSA 145.8K
- CGTX 588.8K
- Earning Date
- TLSA 05-10-2024
- CGTX 11-08-2024
- Dividend Yield
- TLSA N/A
- CGTX N/A
- EPS Growth
- TLSA N/A
- CGTX N/A
- EPS
- TLSA N/A
- CGTX N/A
- Revenue
- TLSA N/A
- CGTX N/A
- Revenue This Year
- TLSA N/A
- CGTX N/A
- Revenue Next Year
- TLSA N/A
- CGTX N/A
- P/E Ratio
- TLSA N/A
- CGTX N/A
- Revenue Growth
- TLSA N/A
- CGTX N/A
- 52 Week Low
- TLSA $0.41
- CGTX $0.34
- 52 Week High
- TLSA $1.74
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- TLSA 65.44
- CGTX 54.28
- Support Level
- TLSA $0.83
- CGTX $0.50
- Resistance Level
- TLSA $0.92
- CGTX $0.64
- Average True Range (ATR)
- TLSA 0.09
- CGTX 0.07
- MACD
- TLSA 0.03
- CGTX 0.02
- Stochastic Oscillator
- TLSA 84.52
- CGTX 67.74
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.